Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Azora Therapeutics, Inc. (DE) (AZR)

Adial Pharmaceuticals delays stockholder vote on four proposals to October 15, 2026

Neutral Impact 2 of 5 shareholder Written later

Adial Pharmaceuticals, Inc. further adjourned the reconvened portion of its 2026 Annual Meeting because it had not yet received Nasdaq's approval of an Initial Listing Application tied to those proposals. Votes on Proposals 3, 4, 5 and 6 remain open, and the meeting will reconvene on October 15, 2026. The filing names Adial Pharmaceuticals, Inc. while the ticker given was AZR, so the company identity should be confirmed.

Key points

  • Proposals 1, 2, 7, 8, 9, 10, 11 and 12 were voted on earlier; votes on Proposals 3, 4, 5 and 6 are still pending.
  • The October 1, 2026 reconvened meeting was adjourned again while Nasdaq approval was still outstanding.
  • The adjourned meeting will reconvene October 15, 2026 at 8:30 a.m. Eastern Time in Charlottesville, Virginia.
  • The record date remains August 17, 2026; stockholders who already submitted proxies need not act unless they want to change their votes.

The filing

CompanyAzora Therapeutics, Inc. (DE) (AZR)
Form8-K, current report
Filed with the SECOct 2, 2026, 4:16 PM ET
Accession number0001213900-26-106395

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.